You're reading the free version. Trader adds the live tape and alerts.
Start tracking
CRVS Award Disclosure
Moore David Scott · SEC Form 4 · Filed Jun 15, 2026
Award
Calculated transaction value
$0
Moore David Scott Director
CRVS
Transaction date
Jun 11, 2026
Public filing date
Jun 15, 2026
Filing lag
Filed 4 days later
CRVS daily price context
Close on/before transaction
$11.6
Jun 11, 2026
First close after public filing
--
Unavailable
30-day return after filing
--
Through Unavailable
Source details
- Reported owner
- Not disclosed
- Source asset code
- Derivative
- Security
- Stock Option (Right to Buy) on Common Stock
- Quantity / price
- 15,000 shares @ $0
- SEC ownership
- Direct
- Transaction code
- A
- Form
- 4
- Filing identifier
- 0001610717-26-000223
Filing cohort
Transactions in this filing
Showing 2 of 2
Trades
2
Issuers
1
Estimated value
$250.24K
Buys / sales
1 / 0
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. CRVS | Buy | Jun 11, 2026 | $250.24K |
| Corvus Pharmaceuticals, Inc. CRVS Current | Award | Jun 11, 2026 | $0 |